Neodyne Biosciences, Inc., Manufacturer of embrace® Advanced Scar Therapy, Receives Notice of Allowance for Korean Patent

Jul 22, 2014, 09:00 ET from Neodyne Biosciences, Inc.

MENLO PARK, Calif., July 22, 2014 /PRNewswire/ -- Neodyne Biosciences, a medical device company focused on the development and commercialization of innovative tissue repair devices to promote healing and minimize scar formation, announced today that it has received a notice of allowance for a Korean Patent entitled "Devices And Bandages For The Treatment Or Prevention Of Scars And/Or Keloids And Methods And Kits Therefore."

The issuance of the Korean Patent will mark the 5th granted international patent in the Neodyne Biosciences portfolio with over 30 additional international patents pending. Neodyne's initial product, embrace® Advanced Scar Therapy is the first scar management product of its kind. Each embrace® dressing is an elastomeric device that has been proven to significantly improve scar appearance in randomized, controlled trials.1,2 embrace® actively relieves the tension surrounding a healing scar to minimize scar formation and uses technology initially developed at Stanford University and subsequently licensed to Neodyne Biosciences.

"This new patent in Korea is an extremely important addition to our intellectual property portfolio," said Bill Beasley, President of Neodyne. "The Korean market represents one of the top 5 worldwide markets for scar mitigation, and this country has been on our radar for quite some time.  We are delighted to have the opportunity to expand our global reach with this relevant and valuable patent, and we anticipate obtaining additional patents in other countries in the near future."

About Neodyne Biosciences, Inc.

Neodyne Biosciences ( is an evidence based company developing and commercializing innovative tissue repair devices to minimize scar formation, restoring both function and aesthetic appearance. The company develops stress-shielding devices capable of controlling the mechanical wound environment to ameliorate post-surgical scarring.

Neodyne Investor Relations Contacts:

Bill Beasley


Michael Fanucchi


1Lim AF, et al. The embrace Device Significantly Decreases Scarring Following Scar Revision Surgery in a Randomized Controlled Trial. Plast Reconstr Surg. 2014;133:398-405.

2Longaker, MT et al. A Randomized Controlled Trial of the embrace® Device to Reduce Incisional Scar Formation. Published ahead of Print - Plast Reconstr Surg. 2014

SOURCE Neodyne Biosciences, Inc.